Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
Studies from H. Gerullis et al further understanding of adverse drug reactions
June 2nd, 2009
According to recent research published in the journal Cancer Chemotherapy and Pharmacology, " To detail tolerance of temsirolimus in a routine practice setting within a compassionate use program for patients with renal cell carcinoma. We treated 32 patients with advanced renal cell carcinoma with temsirolimus within the German compassionate use program on an individual patient basis free of charge according to EU guidelines at our two institutions." "Twenty-five milligrams of temsirolimus was applied weekly in an inpatient clinical setting. Adverse events were classified following National Cancer Institute Common Toxicity Criteria. No dose modification or...
Source: Cancer Weekly (2009-06-02)
|
